Trial reportJournal of attention disorders2014
A pilot study of lis-dexamfetamine dimesylate (LDX/SPD489) to facilitate smoking cessation in nicotine-dependent adults with ADHD.
Trial report in Journal of attention disorders, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 4 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.PloS one · 2020Pooled it
- Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults.The Cochrane database of systematic reviews · 2018Pooled it
- Stimulant treatment of ADHD and cigarette smoking: a meta-analysis.Pediatrics · 2014Pooled it
- Pharmacological Treatment of ADHD in Addicted Patients: What Does the Literature Tell Us?Harvard review of psychiatryPooled it
- Methylphenidate does not influence smoking-reinforced responding or attentional performance in adult smokers with and without attention deficit hyperactivity disorder (ADHD).Experimental and clinical psychopharmacology · 2013Trial
- The co-use of nicotine and prescription psychostimulants: A review of their behavioral and neuropharmacological interactions.Drug and alcohol dependence · 2023Review
- TOBACCO USE DISORDER AND DUAL DISORDERS Joint statement by the Spanish Psychiatry Society and the Spanish Dual Disorders Society.Actas espanolas de psiquiatria · 2022Article
- Substance use through adolescence into early adulthood after childhood-diagnosed ADHD: findings from the MTA longitudinal study.Journal of child psychology and psychiatry, and allied disciplines · 2018Article
- ADHD, Smoking Withdrawal, and Inhibitory Control: Results of a Neuroimaging Study with Methylphenidate Challenge.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018Article
- Ecological momentary assessment of antecedents and consequences of smoking in adults with attention-deficit/hyperactivity disorder.Substance use & misuse · 2014Article
- ADHD, altered dopamine neurotransmission, and disrupted reinforcement processes: implications for smoking and nicotine dependence.Progress in neuro-psychopharmacology & biological psychiatry · 2014Review
- Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction.British journal of clinical pharmacology · 2014Review
- Smoking motivation in adults with attention-deficit/hyperactivity disorder using the Wisconsin inventory of smoking dependence motives.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2014Article
- Effects of smoking abstinence on smoking-reinforced responding, withdrawal, and cognition in adults with and without attention deficit hyperactivity disorder.Psychopharmacology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
objectiveThe goal of this study was to assess the efficacy and tolerability of lis-dexamfetamine dimesylate (LDX) as an adjunct to nicotine replacement therapy in adult smokers with ADHD who were undergoing a quit attempt.
methodsThirty-two regular adult smokers with ADHD were randomized to receive LDX (n = 17) or placebo (n = 15) in addition to nicotine patch concurrent with a quit attempt.
resultsThere were no differences between smokers assigned to LDX versus placebo in any smoking outcomes. Participants treated with LDX demonstrated significant reductions in self-reported and clinician-rated ADHD symptoms. LDX was well tolerated in smokers attempting to quit. DISCUSSION: In general, LDX does not facilitate smoking cessation in adults with ADHD more than does placebo, though both groups significantly reduced smoking. LDX demonstrated efficacy for reducing ADHD symptoms in adult smokers engaging in a quit attempt.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.